Abstract
177Lu-labeled receptor avid peptides and monoclonal antibodies have been effectively used in targeted tumor therapy, owing to the ideally suited decay properties and favourable production logistics of 177Lu [T½ = 6.65 days; Eβ(max) = 497 keV (78.6 %); Eγ = 208 keV (11.0 %)]. The specific activity of 177Lu produced by the (n,γ) route is one of the important criteria, which determines the efficacy of 177Lu-labeled receptor-avid biomolecules. The present article highlights that the specific activity of (n,γ) produced 177Lu cannot be calculated by simply dividing the produced activity by the mass of the target irradiated, unlike other (n,γ) produced medical radioisotopes and there is a significant enhancement of specific activity due to the burn up of the Lu target during irradiation, which is an added advantage towards the utilization of 177Lu in receptor specific therapeutic radiopharmaceuticals.
Similar content being viewed by others
References
Cutler CS, Hennkens HM, Sisay N, Huclier-Markai S, Jurisson SS (2013) Chem Rev 113:858–883
Das T, Pillai MRA (2013) Nucl Med Biol 40:23–32
Banerjee S, Das T, Chakraborty S, Venkatesh M (2012) Radiochim Acta 100:115–126
Kam BLR, Teunissen JJM, Krenning EP, de Herder WW, Khan S, van Vliet EI, Kwekkeboom DJ (2012) Eur J Nucl Med Mol Imaging 39(Suppl 1):S103–S112
Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJM, Kooij PPM, Herder WW, Feelders RA, Eijck CHJ, Jong M, Srinivisan A, Erion JL, Krenning EP (2003) Eur J Nucl Med Mol Imaging 30:417–422
Das T, Bhadwal M, Banerjee S, Sarma HD, Shinto A, Kamaleshwaran KK (2014) J Radioanal Nucl Chem 299:1389–1398
Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ (2005) J Clin Oncol 23:4591–4601
Rasaneh S, Rajabi H, Babaei MH, Daha FJ, Salouti M (2009) Nucl Med Biol 36:363–369
Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP (2008) J Clin Oncol 26:2124–2130
Esser JP, Krenning EP, Teunissen JJ, Kooij PP, van Gameren AL, Bakker WH, Kwekkeboom DJ (2006) Eur J Nucl Med Mol Imaging 33:1346–1351
Das T, Chakraborty S, Banerjee S, Venkatesh M (2007) Appl Radiat Isot 65:301–308
Kwekkeboom DJ, Bakker WH, Kooij PPM, Konijnenberg MW, Srinivasan A, Erion JL, Schmidt MA, Bugaj JL, de Jong M, Krenning EP (2001) Eur J Nucl Med 28:1319–1325
Chakravarty R, Das T, Dash A, Venkatesh M (2010) Nucl Med Biol 37:811–820
Pillai MRA, Chakraborty S, Das T, Venkatesh M, Ramamoorthy N (2003) Appl Radiat Isot 59:109–118
Chakraborty S, Vimalnath KV, Sharad P Lohar, Priyalata Shetty, Ashutosh Dash (2014) J Radioanal Nucl Chem DOI 10.1007/s10967-014-3169-z
Atlas of neutron capture cross sections (1997) IAEA Nuclear Data Section, Vienna
Dvorakova Z, Henkelmann R, Lin X, Türler A, Gerstenberg H (2008) Appl Radiat Isot 66:147–151
Zhernosekov KP, Perego RC, Dvorakova Z, Henkelmann R, Türler A (2008) Appl Radiat Isot 66:1218–1220
Acknowledgments
Research at the Bhabha Atomic Research Centre is part of the ongoing activities of the Department of Atomic Energy, India and fully supported by government funding. The authors are grateful to Dr. Gursharan Singh, Head, Isotope Application and Radiopharmaceuticals Division, Bhabha Atomic Research Centre, for his support. The authors express sincere gratitude to Dr. Ashok Goswami, Head, Radiochemistry Division, Bhabha Atomic Research Centre, for his support in the analysis of samples using ICP-AES technique. The authors are also thankful to the staff members of Irradiation Co-ordination Group of Isotope Application and Radiopharmaceuticals Division for their help.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vimalnath, K.V., Shetty, P., Lohar, S.P. et al. Aspects of yield and specific activity of (n,γ) produced 177Lu used in targeted radionuclide therapy. J Radioanal Nucl Chem 302, 809–812 (2014). https://doi.org/10.1007/s10967-014-3240-9
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10967-014-3240-9